Cargando…

Practical Guidance for the Management of Adverse Events in Patients with KRAS(G12C)-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib

Adagrasib (MRTX849) is a KRAS(G12C) inhibitor with favorable properties, including long half-life (23 h), dose-dependent pharmacokinetics, and central nervous system (CNS) penetration. As of September 1, 2022, a total of 853 patients with KRAS(G12C)-mutated solid tumors, including patients with CNS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Jun, Johnson, Melissa, Barve, Minal, Bazhenova, Lyudmila, McCarthy, Marybeth, Schwartz, Rowena, Horvath-Walsh, Elise, Velastegui, Karen, Qian, Chunlin, Spira, Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Lung Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078892/ https://www.ncbi.nlm.nih.gov/pubmed/36892150 http://dx.doi.org/10.1093/oncolo/oyad051

Ejemplares similares

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS(G12C) Solid Tumors (KRYSTAL-1)
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2022)

Adagrasib: A landmark in the KRAS(G12C)‐mutated NSCLC
por: Tian, He, et al.
Publicado: (2022)

Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRAS(G12C)-Mutant Non-Small Cell Lung Cancer
por: Elkrief, Arielle, et al.
Publicado: (2023)

Diffuse Alveolar Hemorrhage in a Patient Receiving Bevacizumab for Lung Cancer
por: Sethi, Sakshi, et al.
Publicado: (2014)

A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib
por: Brazel, Danielle, et al.
Publicado: (2022)

Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRAS(G12C)-Mutated Non–Small-Cell Lung Cancer Who Have Untreated CNS Metastases
por: Negrao, Marcelo V., et al.
Publicado: (2023)

Health Equity in Patients Receiving Durvalumab for Unresectable Stage III Non-Small Cell Lung Cancer in the US Veterans Health Administration
por: Moore, Amanda M, et al.
Publicado: (2023)

Evaluating the intracranial activity of adagrasib
por: Kotecha, Rupesh, et al.
Publicado: (2023)

Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRAS(G12C)-Mutant Non–Small Cell Lung Cancer
por: Sabari, Joshua K., et al.
Publicado: (2022)

Synthesis of Adagrasib (MRTX849), a Covalent KRAS(G12C) Inhibitor Drug for the Treatment of Cancer
por: Chen, Cheng-yi, et al.
Publicado: (2023)

Adagrasib, a KRAS G12C inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivo
por: Zhang, Yuchen, et al.
Publicado: (2022)

Is investigation of patients with haemoptysis and normal chest radiograph justified?
por: Thirumaran, M, et al.
Publicado: (2009)

Virtual bronchoscopic navigation combined with endobronchial ultrasound to diagnose small peripheral pulmonary lesions: a randomised trial
por: Ishida, Takashi, et al.
Publicado: (2011)

UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer
por: Baldwin, D R, et al.
Publicado: (2011)

Survival of patients with small cell lung cancer undergoing lung resection in England, 1998–2009
por: Lüchtenborg, Margreet, et al.
Publicado: (2014)

Cell migration leads to spatially distinct but clonally related airway cancer precursors
por: Pipinikas, Christodoulos P, et al.
Publicado: (2014)

Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma
por: Sage, Elizabeth K, et al.
Publicado: (2014)

The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancer
por: Alamgeer, Muhammad, et al.
Publicado: (2013)

Reliable EGFR mutation testing in ultrasound-guided supraclavicular lymph node fine-needle aspirates: a cohort study with diagnostic performance analysis
por: Awwad, Amir, et al.
Publicado: (2015)

Precise navigation surgery of tumours in the lung in mouse models enabled by in situ fluorescence labelling with a killer-reporter adenovirus
por: Yano, Shuya, et al.
Publicado: (2015)

ERK and AKT phosphorylation status in lung cancer and emphysema using nanocapillary isoelectric focusing
por: Crosbie, Philip A J, et al.
Publicado: (2016)

What characteristics of primary care and patients are associated with early death in patients with lung cancer in the UK?
por: O'Dowd, Emma L, et al.
Publicado: (2015)

Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score
por: Clive, Amelia O, et al.
Publicado: (2014)

Responding to symptoms suggestive of lung cancer: a qualitative interview study
por: Birt, Linda, et al.
Publicado: (2014)

An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B(12) and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of severe neutropenic toxicity
por: Minchom, A R, et al.
Publicado: (2014)

UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening
por: Field, J K, et al.
Publicado: (2016)

Lifestyle factors and experience of respiratory alarm symptoms in the general population
por: Sele, Lisa Maria Falk, et al.
Publicado: (2015)

Long-term psychosocial outcomes of low-dose CT screening: results of the UK Lung Cancer Screening randomised controlled trial
por: Brain, Kate, et al.
Publicado: (2016)

Differential eligibility of African American and European American lung cancer cases using LDCT screening guidelines
por: Ryan, Bríd M
Publicado: (2016)

Accuracy of transbronchial biopsy as a rebiopsy method for patients with relapse of advanced non-small-cell lung cancer after systemic chemotherapy
por: Ishii, Hidenobu, et al.
Publicado: (2017)

Factors influencing the utilization of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer
por: Lok, Benjamin H., et al.
Publicado: (2017)

Investigation of the international comparability of population-based routine hospital data set derived comorbidity scores for patients with lung cancer
por: Lüchtenborg, Margreet, et al.
Publicado: (2018)

Impact of low-dose CT screening on smoking cessation among high-risk participants in the UK Lung Cancer Screening Trial
por: Brain, Kate, et al.
Publicado: (2017)

A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy‐Naïve Advanced or Metastatic Nonsquamous Non‐Small Cell Lung Cancer
por: Marrone, Kristen A., et al.
Publicado: (2018)

Lung cancer specialists' opinions on treatment for stage I non-small cell lung cancer: A multidisciplinary survey
por: Lammers, Austin, et al.
Publicado: (2018)

Implications for high-precision dose radiation therapy planning or limited surgical resection after percutaneous computed tomography-guided lung nodule biopsy using a tract sealant
por: de Groot, Patricia M., et al.
Publicado: (2017)

Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy
por: Eide, Hanne A., et al.
Publicado: (2018)

Internal dose escalation is associated with increased local control for non-small cell lung cancer (NSCLC) brain metastases treated with stereotactic radiosurgery (SRS)
por: Abraham, Christopher, et al.
Publicado: (2017)

Image enhancement technology in bronchoscopy: a prospective multicentre study in lung cancer
por: van der Heijden, Erik H F M, et al.
Publicado: (2018)

Geographical variations in the use of cancer treatments are associated with survival of lung cancer patients
por: Møller, Henrik, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_s11jqsfqtfaf500mto2k45afob